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Duchenne muscular dystrophy (DMD) is a rare, severe, progressive muscle-wasting disease leading to disability
and premature death. Patients lack the muscle membrane-stabilizing protein dystrophin. Antisense oligonu-
cleotide (AON)-mediated exon skipping is a therapeutic approach that aims to induce production of partially
functional dystrophins. Recently, an AON targeting exon 51 became the first of its class to be approved by the
United States regulators [Food and Drug Administration (FDA)] for the treatment of DMD. A unique aspect of
the exon-skipping approach for DMD is that, depending on the size and location of the mutation, different exons
need to be skipped. This challenge raises a number of questions regarding the development and regulatory
approval of those individual compounds. In this study, we present a perspective on those questions, following a
European stakeholder meeting involving academics, regulators, and representatives from industry and patient
organizations, and in the light of the most recent scientific and regulatory experience.
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Introduction
Duchenne muscular dystrophy (DMD) is a rare, se-vere, progressive muscle-wasting disease. Continuous
efforts to improve the understanding of the disease and to in-
vestigate potential approaches to treat it have brought the field
to the stage of clinical trials and marketing authorization
applications. The most advanced therapies include those that
aim at restoration of the missing protein, dystrophin, using
mutation-specific genetic approaches, such as antisense oligo-
nucleotide (AON)-mediated exon skipping (see Box 1: Du-
chenne Muscular Dystrophy and Exon Skipping). These
developments revealed some as of yet unresolved issues, such
as the identification and use of biomarkers inDMD, the fact that
each AON applies to only a subgroup of patients with this
condition, and the best way to fulfill the criteria for regulatory
approval for the different AONs. The current perspective on
these and other issues was discussed in detail during a DMD
multistakeholder meeting involving representatives from pa-
tient organizations, academia, industry, and European Union
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Box 1: Duchenne Muscular Dystrophy and Exon Skipping
DMD is an X-linked, progressive muscle wasting disease that affects 1 in 5,000 newborn males [2]. The disease is
caused by mutations in theDMD gene that abolish the production of dystrophin protein [3]. Dystrophin links the F-actin in
the cytoskeleton with beta-dystroglycan and the extracellular matrix, through its N- and C-terminal domains, respectively
[4]. Mutations causing the premature truncation of dystrophin translation result in nonfunctional and unstable dystrophin
proteins typically undetectable with standard diagnostic techniques. However, internal deletions or duplications main-
taining the reading frame allow the production of dystrophins that maintain their N- and C-terminal domains. These
dystrophins aremore stable and partially functional and are associated with a less severe and less progressive allelic form of
muscular dystrophy, Becker muscular dystrophy (BMD) [5].
Over 7,000 different mutations have been reported for DMD patients [6,7]. Most patients (*65%) carry large deletions
involving one or more exons, but large duplications (*12%) and small mutations (20%) are frequently reported as well.
The commonality of these mutations is that they all result in nonfunctional dystrophins. However, many DMD patients can
unexpectedly produce trace amounts of BMD-type dystrophins [8].
For example, a deletion of exon 45 is one of the most common deletions found in DMD patients, whereas a deletion of
exons 44 and 45 is generally associated with BMD [9]. Thus, if exon 44 could be bypassed in pre-messenger RNA (mRNA)
transcripts of these DMD patients, this would restore the reading frame and enable the production of a partially functional
BMD-like dystrophin (Fig. 1). In fact, it appears that many patients with a deletion bordering on exon 44, skip exon 44
spontaneously, although at very low levels. This results in slightly increased levels of dystrophin when compared with
DMD patients carrying other deletions, and most likely underlies the less severe disease progression observed in these
patients compared with DMD patients with other deletions [9–11].
The rationale of antisense-mediated exon skipping is to induce the skipping of a target exon to restore the reading
frame (Fig. 1) [12]. For patients with an exon 45 deletion, this would require an AON targeting exon 44. However,
different patients have different mutations and exon 44 skipping would only apply to *8% of patients [7,12]. To
develop the exon-skipping approach for larger groups of patients, AONs targeting additional exons of the gene would
have to be developed, for example, AONs to skip exon 51, which applies to 13%–14% of patients, that is, the largest
group of patients [7,12].
About 20% of DMD patients have deletions that remove critical domains of the dystrophin protein. For these restoring the
reading frame is anticipated not to be therapeutic, since the resulting dystrophin will not be functional, and that patients with
in-frame mutations deleting these domains have DMD rather than BMD [6,8]. Theoretically, AONs could also be used to
induce exon skipping of in-frame exons containing nonsense mutations; indeed this is the strategy commonly used in the
experimental studies in the dystrophicmdxmouse, carrying a nonsensemutation in the in-frame exon 23. For a more in-depth
discussion of the applicability of exon skipping for different mutation types, we refer the reader to a recent review [8].
FIG. 1. Schematic depiction of the reading frame rule and the exon-skipping approach. Top panel: a deletion of exon 45
disrupts the reading frame (exon 44 and 46 do not ‘‘fit’’) and is associated with DMD, whereas a deletion of exon 44 and 45
maintains the reading frame (exon 43 and 46would ‘‘fit’’) and is associated with BMD. Using AONs, the pre-mRNA splicing
process can bemanipulated. In this exampleAONs targeting exon 44 hide this exon from the splicingmachinery, causing exon
43 to be joined to exon 46, which restores the reading frame and allows production of a BMD-like dystrophin. Bottom panel:
antisense-mediated exon skipping is amutation-specific approach. For example, a deletionof exon48–50 requires the skipping
of exon 51 to restore the reading frame and allow the production of a BMD-like dystrophy. AONs, antisense oligonucleotide;
BMD, Becker muscular dystrophy; DMD, Duchenne muscular dystrophy; mRNA, messenger RNA.
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(EU) drug regulatory agencies. A policy view, highlighting
the main learnings for orphan drug development in EU, and
stressing the importance of stakeholder communication, has
been published as a result of this collaboration [1].
In this perspective it is our intention to continue and outline
the discussion pertaining specifically to the exon-skipping
approach in DMD, discuss the relevant regulatory topics and
critical questions, such as the use of adequate biomarkers as
potential surrogate markers in AON drug development, and
whether class approval is possible for DMD AONs. We will
also include our recommendations on how to best approach
the centralized regulatory system in the EU to minimize time
and resources for drug developers, and guarantee that drugs,
benefiting patients suffering from this devastating condition,
reach them in the fastest way possible.
From Proof-of-Concept to Drug Approval:
Current Experience
Proof-of-concept that the antisense exon-skipping ap-
proach indeed could restore dystrophin protein expression
came from tests in patient and animal model-derived cell
culture experiments and local AON injections in dystrophic
mice [13–15], followed by systemic treatment experiments in
mouse and dog models [16–18]. AONs have been developed
to skip each dystrophin exon [19,20]. However, since exon 51
AONs apply to the largest subgroup of patients, they were the
first to be transferred into clinical programs. Two AONs,
based on different chemistries, were evaluated in various
clinical trials, a 2¢O-methyl phosphorothioate (2OMePS)-
modified AON—drisapersen and a phosphorodiamidate
morpholino oligomer (PMO)—eteplirsen [21–30]. Both com-
pounds were able to restore dystrophin expression after local
injection [26,29]. In the clinical setting each compound fol-
lowed a different clinical program.
Drisapersen has been tested in various clinical trials in over
300 patients for up to 4 years, most often using a 6mg/kg
weekly subcutaneous injection regimen [21,24–26,30]. In
two small placebo-controlled studies, younger patients (6–8
years) treated with drisapersen walked a longer distance in
6min (six-minute walk distance [6MWD]) as compared with
placebo, although this difference was not statistically sig-
nificant and not observed in a large phase 3 trial involving a
more heterogeneous patient population, for example, patients
aged 5–16 years. Side effects included injection site reactions
(severe in some cases), severe thrombocytopenia in a small
percentage of treated subjects, and significant renal effects in
another small subset of treated subjects.
Marketing authorization applications were filed with the
Food and Drug Administration (FDA) and the European
Medicines Agency (EMA) mainly based on post hoc analysis
in selected cohorts, where a therapeutic effect was speculated
to be most likely measurable by the 6MWD. The FDA de-
clared that drisapersen was not approvable on the basis of
data presented in the new drug application, whereas the ap-
plication at EMA was withdrawn by the applicant before the
evaluation was completed [31,32]. At the same time, it was
announced that the clinical development of drisapersen was
stopped, in lieu of the identification of the next generation of
exon 51 skipping AONs [21,31].
Eteplirsen, another AON targeting exon 51-skippable
DMD mutations in patients, has been tested in multiple
clinical trials, generally using a dosing regimen of weekly
intravenous doses of 30 or 50mg/kg [21,27,28]. In an
open-label study that has been ongoing for over 4 years, 10
ambulant US patients appeared to have a slower disease
progression than matched untreated natural history controls
from Italy and Belgium as measured by the 6MWD [28]. No
clear treatment-related side effects were observed.
Eteplirsen recently received accelerated approval from the
FDA, based on pharmacodynamic effects with minimal in-
creases in dystrophin levels in biopsies from some treated
patients, with binding postapproval commitments issued by
the FDA to assess functional effects and clinical benefit in
additional trials before 2021 [21,33]. This application was more
recently submitted to EMA and is currently under review.
While eteplirsen approval provides a treatment option for
*13% of DMD patients in the United States, still no AONs
are available for the majority of patients, and AONs targeting
additional exons are still in the development phase. To in-
crease the availability of exon skipping medicinal products
in clinical practice that could potentially address the needs
of larger groups of DMD patients, more data need to be
gathered from all aspects of pharmaceutical development
for these AONs.
Clinical Development of Additional AONs
Beyond the First Approved AON:
Is There Room for Extrapolation?
Media have widely covered the controversy related to the
FDA approval of the first AON in DMD (eteplirsen) [21].
Nevertheless, the approval brought hope that the AON ap-
proach is indeed viable for this condition and should be a
stimulus for further research and development in the AON
field. The clinical development of drisapersen has shown that
placebo-controlled trials [21,30] are feasible for some of the
subgroups of DMD patients. Currently, exon-skipping trials
focus on exons that could be skipped in 6%–14% of patients
for each product [12], where the numbers are sufficient to
conduct trials in internationally standardized cohorts.
Due to the variability of clinical course in DMD individ-
uals, the already relatively advanced stage of disease when
AONs are started in clinical trials, relatively large cohorts of
affected individuals are required to unequivocally demon-
strate clinical efficacy. These developments are expected to
provide a significant amount of data on the clinical behavior
of various AONs in DMD that could then be used to properly
support the development of a number of additional AONs that
apply to smaller patient numbers.
When dealing with trials that address smaller patient pop-
ulations, the clinical development becomes more challenging,
because there will be fewer eligible patients, with less oppor-
tunity to recruit a homogeneous patient population, for exam-
ple, with respect to age and disease stage. This will probably
hamper the performance of randomized placebo-controlled
trials, not only because of eligibility and recruitment issues, and
the expected length of the trials, but also because of problems
related to the interpretation of the observed treatment effects.
In cases where AONs have already been approved, and
where comprehensive data on their efficacy and safety are
available, the requirements to approve additional AONs of
the same chemistry may change, based on the accumulated
evidence and knowledge about the licensed medicinal
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products. In these cases, partial extrapolation might be a
possible strategy, to supplement the available data for a
specific AON in development, with data that are likely to be
applicable to all members of the class, for example, certain
common safety characteristics. The consideration of such an
approach would, however, rely heavily on having a clear
understanding of the disease progression in the specific
subgroup of patients (depending on their characteristics, eg,
genetic defect), and of the pharmacology of the compound
and its expected effect size in both pharmacodynamic
markers and in clinical endpoints.
Despite the fact that it is expected that the AONs of a
given chemistry should have comparable pharmacokinetic
and pharmacodynamic properties, these will not be neces-
sarily identical. The level of difference will vary according to
chemical modifications, and sequence composition of the
AONs, which may result in a significant difference in the
AONs’ clinical behavior.
Nevertheless, certain characteristics of the AONs’ chem-
istry could give experts grounds to believe that the different
compounds will share a number of common properties. The
PMO chemistry is charge neutral and so far only very limited
differences have been observed between AONs of different
lengths and/or sequence composition in pharmacokinetic and
pharmacodynamic properties in preclinical safety tests [34].
The 2OMePS-modified AONs are negatively charged and
can bind serum proteins with varying affinity based on AON
length and/or nucleotide composition. Hence, while the
overall class characteristics for phosphorothioate oligonu-
cleotides are similar, there can be quantitative differences, for
example, in biodistribution and side effect profiles, which
have been observed in animal models and clinical trials [35].
Furthermore, certain sequence motifs (CpG) have been re-
ported to be associated with inflammation [36], although
these can be avoided with specific AON designs.
Finally, while generally there is good correlation between
activity in cultured cells and animal models for AONs, ex-
ceptions have been reported [18]. For all of the above-
mentioned reasons, it is expected that a certain amount of
preclinical and clinical data will always have to be generated
to confirm the hypothesized efficacy and make assumptions
on the expected safety profile.
The discussion on the appropriateness of potential ex-
trapolation of data from other AONs will have to take into
account the totality of data generated during the whole drug
development. Ensuring the availability of as much robust
data as possible, to clearly establish the safety pharma-
cology, pharmacokinetic behavior, and pharmacodynamic
effects of the drug, will be necessary to help identify the
gaps that could benefit from any type of extrapolation. The
level and appropriateness of potential extrapolation may be
discussed in advance. In fact, it is strongly recommended
that the intended drug development, trial designs, and ex-
trapolation strategies be discussed at an early stage with the
regulators through the available platforms for scientific di-
alogue [37].
In addition to developing AONs for additional exons, de-
veloping more efficient AONs for the same exons is another
possible drug development strategy. It has to be kept in mind
that the orphan drug regulation stipulates that a company with
successful marketing authorization of their medicinal prod-
uct acquires EU market exclusivity for 10 years [38].
In practice, this poses several challenges for future de-
velopments. For instance any new AON targeting the same
exon (eg, of a different chemistry but aiming at the same
target population) may either be concluded to be similar or
nonsimilar in the context of the orphan legislation. When it is
similar, the AON may come to the market through a dero-
gation, in which case significant benefit would still need to be
established. When the AON would be concluded not to be
similar, it can come to the market as an orphan medicinal
product if providing significant benefit for the patients, as
defined in the legislation [39]. The provision of significant
benefit is not limited to improved clinical efficacy, but could
also mean an improved safety profile, or a more tolerable
route of administration.
Development of AONs for Very Small Groups
of Patients
Both drisapersen and eteplirsen, (which induce exon 51
skipping), apply to only 13%–14% of DMD patients. To al-
low for treatment of additional groups of patients, additional
AONs targeting other exons have to be developed and mar-
keted. Currently, clinical trials with AONs targeting exon 45
and 53 have been initiated [40], because a separate devel-
opment program has to be performed for each compound. For
exons where skipping applies to relatively larger patient
groups, this is not an insurmountable problem. However, for
most exons, the applicability per exon is <1% of patients (eg,
exon 49 skipping would apply to only 0.02% of all patients),
which poses challenges in their clinical development [41].
While large, controlled clinical studies may not be feasible
for the limited patient numbers of certain DMD subpopula-
tions, drug developers should focus on collecting as much
information as possible that will allow for a benefit/risk
evaluation to be performed by the decision makers on the
specific AON (both in terms of initial regulatory approval and
later on for reimbursement discussions). It is recommended
that in cases where data are impossible to collect, methods of
extrapolation based on data-driven scientific methods should
be considered.
The DMD community has put forward the proposal for
‘‘platform approval’’ or ‘‘class approval’’ as a way to tackle
the challenge of developing AONs for small groups of pa-
tients. In short, this represents the idea to seek approval for all
AONs of certain chemistry as a group and not as individual
applications. The DMD community expected that this could
be discussed with the regulatory agencies after sufficient
safety and efficacy data had been obtained for a number of
DMD exon-skipping AONs. However, according to the
current legislation in the EU, different medicinal products are
evaluated and authorized individually, on the basis of their
specific risks and benefits (article 6 and 8 of the Directive
2001/83/EC of the legislation [42]).
The assessment of what constitutes a separate me-
dicinal product is not limited only to the differences in the
active substance, but also considers factors, such as pro-
duction process, pharmaceutical form, excipients, and oth-
ers, and even legal provisions such as ownership of the
rights to market the product. From a regulatory and scien-
tific perspective, the fact that the different AONs tar-
get different exons, would likely qualify them as different
medicinal products.
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Even in the case where the same exon is targeted, it could
be argued that AONs of similar chemistry (ie, belonging to
the same class) may act in a different manner based on
differences in their composition and length, which may re-
sult in differences in their pharmacokinetic and pharma-
codynamic profiles, and as a consequence may also have
different efficacy and safety outcomes. This will also
qualify them as different medicinal products that will need
to take the regulatory route to approval separately. Never-
theless, some level of extrapolation based on accumulated
data from previously developed AONs could be discussed.
It must always be kept in mind, however, that these data
will have to be legally available to the applicant to be used
in different regulatory submissions (marketing applica-
tion dossiers).
Dystrophin Restoration as a Biomarker for Small Trials
Exon skipping aims to restore or increase dystrophin
expression in DMD patients’ muscle fibers. Dystrophin
quantification was therefore considered as an obvious
pharmacodynamic biomarker, but to be used in clinical de-
velopment as a surrogate for functional outcome, ideally this
biomarker needs to be validated. This means that evidence
for the correlation between dystrophin levels and clinical
outcomes is required. Validating dystrophin quantification is
not a straightforward process [43,44], and involves dealing
with a number of specific issues:
(1) Dystrophin is a large protein that is expressed at very
low levels in skeletal muscles, which makes quanti-
fication difficult, also because there is no reference
standard that can be utilized.
(2) Dystrophin levels vary among unaffected individuals,
but also among muscles and muscle fibers within a
certain individual.
(3) The progressive replacement of muscle by fibrotic and
adipose tissue in DMD patients hampers absolute quan-
tification, since these tissues do not express dystrophin.
Moreover there is variability of muscle pathology be-
tween muscles, but also within individual muscles.
(4) A muscle biopsy involves a tiny sample of a single
muscle. First, it is possible that a biopsy is obtained
only containing very few muscle fibers, which makes
quantification impossible. Second, determination of
the pattern and level of dystrophin expression in a
particular muscle biopsy of a given muscle in a given
patient may not necessarily be representative of every
single muscle in the same patient.
(5) Different internally shortened dystrophins will be
formed through exon skipping for patients with dif-
ferent deletions (eg, the dystrophin formed after
skipping exon 51 will differ for a deletion of exon
49–50 vs. a deletion of exon 52 and both will differ
from the dystrophin formed after exon skipping for a
deletion of exon 45). For most of these dystrophin
molecules it is known that they may be functional
because they are found in muscles of BMD individuals
[6]. However, the functionality of other rare in-frame
mutations has never been proven as the corresponding
BMD patients remain uncharacterized. In such cases, it
will be important to confirm the restoration of the
proper localization of dystrophin-associated proteins in
a muscle biopsy by immunofluorescence analysis.
(6) While it is known that the presence of low levels of
dystrophin since birth are associated with a slower
disease progression [10,11], dystrophin expression
induced by exon skipping could only become effec-
tive at the time of intervention, when the pathological
process in the muscles have already led to substantial
damage and loss of muscle mass leading to muscle
weakness. A newly produced truncated form of dys-
trophin needs to be correctly localized and integrated
in the protein complex to become functional. It is not
known whether this occurs in the context of a dys-
trophic muscle in a DMD patient in the same way as
in a BMD patient. As it is anticipated that the muscle
quality at the time of intervention will influence the
therapeutic effect, it cannot be assumed that restoring
the similar low levels of dystrophin will cause the
same effect on disease progression as having low
levels of dystrophin from birth.
Currently, the available data are insufficient to establish a
correlation between dystrophin levels and clinical function
for various stages of disease. The only indirect inference
derives from different animal models in which dystrophin
restoration was induced at different stages of muscle pa-
thology [45]. While these studies have demonstrated func-
tional benefit for dystrophin re-expression, it is not clear
how to translate these preclinical data to the human scenario.
In the regulatory submissions up to now, eteplirsen was
approved in the United States based on an increase in dys-
trophin expression in eteplirsen-treated patients, and even if
the levels of expression were very low [21] dystrophin ex-
pression served as a surrogate endpoint for this approval.
The current EMA regulatory position on the subject, as
reflected in the published EMA DMD guideline [46], is
that the quantification of dystrophin expression still has
limitations that prevent its use as a surrogate measure for
efficacy, that is, to be used as the only endpoint in a confir-
matory trial.
This is due to two main reasons: the first is related to the
limitations of dystrophin quantification in muscle biopsies (as
discussed earlier in this section); the second is related to the
fact that a clear relationship between the restoration of low
levels of dystrophin and a functional outcome, clinically most
important to the patients, has not been established so far. As
such, the levels of dystrophin are not considered sufficiently
validated in the regulatory sense, for the context of use as
primary efficacy endpoints. However, in cases where the
mechanism of action of the therapy is related to the restora-
tion of dystrophin expression, detection of dystrophin in
muscle tissue could serve as a pharmacodynamic marker for
proof of concept.
Drug developers should be aware that a dedicated proce-
dure is in place at EMA for the qualification of biomarkers for
a specific intended use in the context of research and devel-
opment into pharmaceuticals [47]. This procedure provides
a platform for discussion on any potential novel method-
ology that is to be used in the drug development process.
During a continuous early dialogue, the gaps that need to
be filled by appropriate data will be identified, and the ap-
propriate context of use determined. The specific biomarker/
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tool is then officially validated/qualified for its use in regu-
latory submissions.
Regulatory Tools and Incentives in the Centralized
EU Regulatory System
Examples from other fields show that early engagement
with the regulatory authorities has proven to be beneficial in
providing useful guidance and scientific advice, leading to a
higher success rate of subsequent marketing authorizations
[48,49]. It is useful to be aware of the platforms for early
dialogue, and of the respective incentives that the EMA
provides, to better guide drug development and guarantee
less queries during potential future assessment. Here, the
main features of the platforms that may be most relevant for
AON developers are introduced:
Innovation Task Force
The Innovation Task Force (ITF) [50] is a multidisciplin-
ary group that includes scientific, regulatory, and legal
competences. It is a discussion platform for early dialogue
with applicants, in particular micro-, small-, and medium-
sized enterprises (SMEs) to proactively identify scientific,
legal, and regulatory issues of emerging therapies and tech-
nologies. This format also allows for a face-to-face meeting
with relevant experts.
Priority medicines scheme
Priority medicines (PRIME) [51] is a scheme launched by
EMA to enhance support for the development of medicines
that target an unmet medical need. This voluntary scheme is
based on enhanced interaction and early dialogue with de-
velopers of promising medicines, to optimize development
plans and speed up evaluation so these medicines can reach
patients earlier.
Scientific advice and protocol assistance
EMA also provides scientific advice and protocol assis-
tance to companies [37]. EMA can give scientific advice to a
company on the appropriate tests and studies in the devel-
opment of a medicine. This is designed to facilitate the de-
velopment and availability of high-quality, effective, and
acceptably safe medicines, for the benefit of patients. Com-
panies can request scientific advice from the EMA at any
stage of development of a medicine, regardless of whether
the medicine is eligible for the centralized authorization
procedure.
Scientific advice helps the company to make sure that it
performs the appropriate tests and studies, so that no major
objections regarding the design of the tests are likely to be
raised during evaluation of the marketing authorization ap-
plication. Companies developing orphan medicines for rare
diseases can receive answers to questions relating to the
criteria for authorization of an orphan medicine, and once
they have orphan drug designation also have access to pro-
tocol assistance [52].
Orphan designation
Rare diseases are defined as life-threatening or chroni-
cally debilitating conditions that affect no more than 5 in
10,000 people in the EU, equivalent to fewer than 250,000
people for each disease. Medicines developed for rare dis-
eases are termed ‘‘orphan medicines’’ in the regulatory
world. To support drug development in these conditions, the
EU offers a range of incentives to encourage the develop-
ment of these medicines [52]. In addition to the main reg-
ulatory incentive of 10-year market exclusivity already
mentioned before, these also include significant fee reduc-
tions, as well as administrative and regulatory support, es-
pecially for SMEs [53].
Small- and medium-sized enterprises
EMA addresses the unique needs of SMEs through the
SME office [54]. This dedicated interface has the sole remit
of providing regulatory, financial, and administrative assis-
tance to small pharmaceutical companies. This includes a
wide range of activities to support SMEs, such as direct as-
sistance on regulatory matters, fee reductions and exemp-
tions, assistance with translations, inclusion in an online SME
register, and workshops and training sessions.
Future Perspective
The therapeutic development of AON-mediated exon
skipping for DMD has come a long way. Exon 51 skipping is
now an approved treatment in the United States, while
evaluation by EMA is pending. However, this applies only to
13% of DMD patients and thus far only those in the United
States. Developing additional AONs targeting other exons
will be needed to increase the number of patients to which
this approach applies. For AONs applying to smaller groups
of patients, this will be increasingly challenging. Some
proposals, such as platform approval, sound on face value
appealing from a scientific perspective, but do not comply
with the current regulatory system and legislation, whereby
different medicinal products are individually assessed.
Nevertheless, as knowledge obtained for AONs in DMD
continues to accumulate, extrapolation approaches may be
discussed with regulatory authorities to try and accelerate the
development of future AONs. These therapies not only rep-
resent a potentially disease-modifying path for one of the
most devastating neuromuscular diseases, but also help us to
foresee a future for personalized genetic therapies in neu-
rology [55].
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